Neurological disorders news - the latest biotech news

Home Neurological disorders Page 14

Latest Posts

Alzheimers

News and Trends 24 Nov 2015

2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease?

Since both Alzheimer’s Disease and Parkinson’s combined affect up to 50 million people worldwide, it is no wonder this new wave of break-through milestones is getting the industry excited… The Central Nervous System (CNS) comprises many complex tissues and highly specialized cell types, mutation in which can cause an array of deadly and chronic diseases. […]

November 24, 2015 - 9 minutesmins - By Dani Bancroft

Proteros epigenetics 2

News and Trends 17 Nov 2015

Epigenetics Drug Discovery has a New Champion!

Last week at BIO-Europe 2015 in Munich, I had the opportunity to meet Torsten Hoffmann, CSO of Proteros who told me more about the recent incursion of his company in the Epigenetics space! Proteros is a leader of the Structural Biology field. So, what is this field exactly? Usually, when a Pharmaceutical company is looking […]

November 17, 2015 - 4 minutesmins - By Joachim Eeckhout

swissmedic newron xadago zambon parkinsons

News and Trends 16 Nov 2015

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s Disease. Zambon, is a Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases. Its partner, Newron Pharmaceuticals, is a research and development biotech from northern […]

November 16, 2015 - 2 minutesmins - By Julie Lellouche

Dementia discovery fund

News and Trends 26 Oct 2015

Dementia could bankrupt us all… The Biotech ‘A’ Team comes to the rescue!

The fight against Alzheimer‘s with the World Health Organization and the G8 Dementia Summit rallies a collective of biotech industry specialists also wanting in on the battle front. The latest development in the Dementia Discovery Fund (DDF) includes US Biogen‘s dramatic cuts to redirect $250M into the Neurodegenerative disease venture, and investment into $100M ‘A’ […]

October 26, 2015 - 3 minutesmins - By Dani Bancroft

Neurodegenerative disease

News and Trends 15 Oct 2015

Neurodegenerative Disease in the UK: Takeda, NIHR & UCL Research Collaboration

Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University College London‘s Institute for Neurology and their NHS teaching hospital to search for novel gene targets with significance in neurodegenerative disease. Takeda has already got massive Alzheimer‘s clout in the industry for its blockbuster Galantamine Hydrobromide (branded REMINYL in Japan), […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

YSIOS

News and Trends 15 Oct 2015

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

ADVERTISEMENT

Neuroblastoma1

News and Trends 14 Oct 2015

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

New Oncology from Cologne (Germany) is a biotech which today published a paper in Nature on tumor-profile recognition of cancer of the sympathetic nervous system (Neuroblastoma) in conjunction with the latest research at the University of Cologne. The research team has found a new way to diagnose infants with the deadly high-risk version of Neuroblastoma, which […]

October 14, 2015 - 4 minutesmins - By Dani Bancroft

Alzheimers

News and Trends 9 Oct 2015

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

Scientific Animations Ltf

News and Trends 1 Oct 2015

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP). The last decade has been fairly […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

Julie

News and Trends 28 Sep 2015

New Smart Collaboration of Nestlé and AC Immune Against Alzheimer’s disease

Nestlé Institute of Health Sciences (NIHS) is teaming up with the Swiss AC Immune to develop a new minimally invasive Tau diagnostic assay for early diagnosis of Alzheimer’s disease. Alzheimer’s disease has a new case every three seconds, totaling up to 9.9 million new cases of dementia every year. To combat this, AC Immune will […]

September 28, 2015 - 2 minutesmins - By Julie Lellouche

Amsterdam

News and Trends 22 Sep 2015

UniQure’s cure for rare Lysosomal disease ready for phase III trial

UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial targeting a rare Lysosomal disease. This has granted fast-track approval to launch its phase III trial for children with Sanfilippo Type B (MPS-III) in collaboration with France’s Institut Pasteur. UniQure is the Amsterdam gene-therapy biotech with a lot going on. Last year […]

September 22, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Jul 2015

AC Immune receives Milestone Payment for Alzheimer Antibody

AC Immune received a first milestone payment from Roche’s subsidiary Genentech. The latter picked up a potential Alzheimer’s drug worth developing towards clinical trials. The collaboration began in 2012 with Genentech’s promising milestone payments amounting to more than €384M (CHF400M). Alzheimer’s disease will be one of the biggest burdens of tomorrow’s society showing a dramaticaly […]

July 17, 2015 - 2 minutesmins - By Philip Hemme

ADVERTISEMENT